Biomarker discovery: Identification of a growth factor gene signature

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 1, 2009, Pages 92-96

  Loboda, A ^a,b   Nebozhyn, M ^a,b   Cheng, C ^b   Vessey, R ^b   Huang, P ^a   Dai, H ^b   Watters, J W ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ROSETTA INPHARMATICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; WORTMANNIN;

BREAST CANCER; DOWN REGULATION; DRUG EFFECT; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; REVIEW; TUMOR; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BIOLOGICAL MARKERS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC MARKERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 67650596629     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.48     Document Type: Review

References (20)

1. Watters, J.W. & Roberts, C.J. Developing gene expression signatures of pathway deregulation in tumors. Mol. Cancer Ther. 5, 2444-2449 (2006).
2. Bild, A.H. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357 (2006).
3. Cully, M., You, H., Levine, A.J. & Mak, T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6, 184-192 (2006).
4. Hughes, T.R. et al. Expression profling using microarrays fabricated by an inkjet oligonucleotide synthesizer. Nat. Biotechnol. 19, 342-347 (2001).
5. Marton, M.J. et al. Drug target validation and identifcation of secondary drug target efects using DNA microarrays. Nat. Med. 4, 1293-1301 (1998).
6. Falls, D.L. Neuregulins: functions, forms, and signaling strategies. Exp. Cell Res. 284, 14-30 (2003).
7. Elstrom, R.L. et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 64, 3892-3899 (2004).
8. Lum, J.J. et al. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev. 21, 1037-1049 (2007).
9. Plas, D.R. & Thompson, C.B. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24, 7435-7442 (2005).
10. Cantley, L.C. & Neel, B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/ AKT pathway. Proc. Natl. Acad. Sci. USA 96, 4240-4245 (1999).
11. Bouchard, C., Marquardt, J., Bras, A., Medema, R.H. & Eilers, M. Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins. EMBO J. 23, 2830-2840 (2004).
12. Bernard, S. & Eilers, M. Control of cell proliferation and growth by Myc proteins. Results Probl. Cell Difer. 42, 329-342 (2006).
13. Dai, H. et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res. 65, 4059-4066 (2005).
14. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
15. DeFeo-Jones, D. et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specifc Akt/PKB family members. Mol. Cancer Ther. 4, 271-279 (2005).
16. van de Vijver, M.J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
17. van 't Veer, L.J. et al. Gene expression profling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
18. Saal, L.H. et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc. Natl. Acad. Sci. USA 104, 7564-7569 (2007).
19. Saal, L.H. et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65, 2554-2559 (2005).
20. Harris, L.N. et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 8, R66 (2006).